Oragenics Inc. Files Q3 2024 10-Q

TL;DR

Oragenics Q3 10-Q filed. Shows preferred stock details and Q3/YTD performance.

AI Summary

Oragenics Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position, including its preferred stock series (A, B, C, F) as of September 30, 2024, and December 31, 2023. It also covers the company's operations for the third quarter of 2024 and the first nine months of 2024.

Why It Matters

This filing provides investors with a crucial update on Oragenics' financial health and operational status for the third quarter of 2024, impacting investment decisions.

Risk Assessment

Risk Level: medium — The filing is a standard quarterly report, but the company's financial performance and specific details within the report could indicate varying levels of risk.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
• 2024-11-13 — Filing Date (Shows when the company submitted this quarterly report to the SEC.)
• Q3 2024 — Quarterly Performance (Represents the financial results for the three months ending September 30, 2024.)

Key Players & Entities

• ORAGENICS INC (company) — Filer of the 10-Q report
• 20240930 (date) — End of the reporting period
• 20241113 (date) — Filing date
• Series A Preferred Stock (company) — Financial instrument detailed in the filing
• Series B Preferred Stock (company) — Financial instrument detailed in the filing
• Series C Preferred Stock (company) — Financial instrument detailed in the filing
• Series F Preferred Stock (company) — Financial instrument detailed in the filing

FAQ

Filing Documents

• form10-q.htm (10-Q) — 763KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-045067.txt ( ) — 3346KB
• ogen-20240930.xsd (EX-101.SCH) — 29KB
• ogen-20240930_cal.xml (EX-101.CAL) — 36KB
• ogen-20240930_def.xml (EX-101.DEF) — 92KB
• ogen-20240930_lab.xml (EX-101.LAB) — 239KB
• ogen-20240930_pre.xml (EX-101.PRE) — 174KB
• form10-q_htm.xml (XML) — 353KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 3 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Changes in Shareholders' Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 24 Item 4.

Controls and Procedures

Controls and Procedures 24

– OTHER INFORMATION

PART II – OTHER INFORMATION 25 Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 27 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 27

Signatures

Signatures 30 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL Oragenics, Inc. Condensed Consolidated Balance Sheets September 30, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 3,144,049 $ 3,483,501 Prepaid expenses and other current assets 969,294 382,273 Total current assets 4,113,343 3,865,774 Prepaid research and development expense 1,090,750 1,090,750 Operating lease right-of-use assets - 9,811 Total assets $ 5,204,093 $ 4,966,335 Liabilities and Shareholders' Equity Current liabilities: Accounts payable and accrued expenses $ 1,607,114 $ 1,475,667 Short-term notes payable 519,392 312,703 Operating lease liabilities - Current - 9,811 Total liabilities 2,126,506 1,798,181 Shareholders' equity: Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, - 0 - and - 0 - Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at September 30, 2024 and December 31, 2023, respectively 1,592,723 1,592,723 Common stock, $ 0.001 par value; 350,000,000 shares authorized and 9,387,547 and 3,080,693 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 9,388 3,081 Additional paid-in capital 214,912,523 207,790,604 Accumulated Deficit ( 213,437,047 ) ( 206,218,254 ) Total shareholders' equity 3,077,587 3,168,154 Total liabilities and shareholders' equity $ 5,204,093 $ 4,966,335 The accompanying notes to the condensed consolidated financial statements are an integral part of these statements. 3 Oragenics, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2024 2023 2024 2023 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 (Unaudited) (Unaudited) Grant revenue $ - $ 7,466 $ - $ 37,653 Operating e

View Full Filing

View this 10-Q filing on SEC EDGAR